VEA
FOLD

Virtus ETF Advisers’s Amicus Therapeutics FOLD Stock Holding History

Virtus ETF Advisers’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,523
Closed -$21.7K – 514
2025
Q4 		$21.7K Sell
1,523
-3,000
-66% -$29.5K 0.01% 438
2025
Q3 		$35.6K Hold
4,523
– – 0.02% 406
2025
Q2 		$25.9K Sell
4,523
-14,129
-76% -$91.2K 0.02% 414
2025
Q1 		$152K Sell
18,652
-15,797
-46% -$146K 0.1% 248
2024
Q4 		$325K Buy
34,449
+3,510
+11% +$36.5K 0.13% 234
2024
Q3 		$330K Hold
30,939
– – 0.15% 222
2024
Q2 		$307K Buy
30,939
+335
+1% +$3.44K 0.15% 226
2024
Q1 		$361K Buy
30,604
+4,403
+17% +$56.3K 0.19% 208
2023
Q4 		$372K Buy
26,201
+3,324
+15% +$37.7K 0.24% 177
2023
Q3 		$278K Sell
22,877
-2,959
-11% -$38.2K 0.17% 210
2023
Q2 		$325K Buy
25,836
+1,097
+4% +$13K 0.19% 182
2023
Q1 		$274K Buy
24,739
+438
+2% +$5.4K 0.15% 263
2022
Q4 		$297K Sell
24,301
-5,397
-18% -$60.8K 0.15% 271
2022
Q3 		$310K Buy
29,698
+435
+1% +$4.85K 0.12% 272
2022
Q2 		$314K Sell
29,263
-6,537
-18% -$53.8K 0.12% 263
2022
Q1 		$339K Hold
35,800
– – 0.15% 163
2021
Q4 		$413K Sell
35,800
-6,869
-16% -$76.6K 0.16% 138
2021
Q3 		$407K Sell
42,669
-3,907
-8% -$40K 0.18% 169
2021
Q2 		$449K Buy
46,576
+20,375
+78% +$199K 0.18% 182
2021
Q1 		$259K Buy
26,201
+714
+3% +$11.1K 0.11% 280
2020
Q4 		$588K Sell
25,487
-27,987
-52% -$572K 0.24% 120
2020
Q3 		$755K Buy
53,474
+4,504
+9% +$65.6K 0.4% 96
2020
Q2 		$738K Sell
48,970
-13,426
-22% -$164K 0.35% 93
2020
Q1 		$577K Sell
62,396
-5,265
-8% -$50K 0.24% 158
2019
Q4 		$659K Buy
67,661
+6,608
+11% +$60.5K 0.11% 166
2019
Q3 		$490K Sell
61,053
-10,267
-14% -$111K 0.1% 181
2019
Q2 		$890K Sell
71,320
-2,333
-3% -$29.6K 0.19% 157
2019
Q1 		$1M Buy
73,653
+16,226
+28% +$198K 2.13% 7
2018
Q4 		$550K Buy
57,427
+28,582
+99% +$314K 0.09% 67
2018
Q3 		$349K Sell
28,845
-20,610
-42% -$288K 0.04% 179
2018
Q2 		$772K Sell
49,455
-9,381
-16% -$142K 0.68% 50
2018
Q1 		$885K Buy
58,836
+31,595
+116% +$481K 0.77% 60
2017
Q4 		$392K Sell
27,241
-10,982
-29% -$151K 0.49% 56
2017
Q3 		$576K Buy
38,223
+3,496
+10% +$46.2K 0.08% 81
2017
Q2 		$350K Sell
34,727
-13,116
-27% -$106K 0.05% 86
2017
Q1 		$341K Buy
47,843
+4,587
+11% +$29K 0.06% 125
2016
Q4 		$215K Buy
43,256
+2,551
+6% +$17.7K 0.06% 171
2016
Q3 		$301K Hold
40,705
– – 0.15% 99
2016
Q2 		$222K Buy
40,705
+13,285
+48% +$92.9K 0.16% 122
2016
Q1 		$232K Buy
+27,420
New +$194K 0.32% 67

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Virtus ETF Advisers's FOLD Position: Q1 2026 in Review

Virtus ETF Advisers sold out of Amicus Therapeutics (FOLD) in Q1 2026, closing a stake of 1,523 shares — an estimated $21.7K sold.

Virtus ETF Advisers first reported a position in FOLD in Q1 2016 and held it in 40 quarters. The position peaked at $1M in Q1 2019. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Virtus ETF Advisers reported no remaining Amicus Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Virtus ETF Advisers sold 1,523 Amicus Therapeutics shares in Q1 2026, an estimated $21.7K.
  • Virtus ETF Advisers first reported a position in Amicus Therapeutics in Q1 2016 and held it in 40 quarters.
  • Virtus ETF Advisers's Amicus Therapeutics position peaked at $1M in Q1 2019.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Virtus ETF Advisers's 13F filing for Q1 2026, filed 14 May 2026.